(CCUG)$_n$ RNA toxicity in a Drosophila model of myotonic dystrophy type 2 (DM2) activates apoptosis

Vildan Betul Yenigun$^{1,2,3,*}$, Mario Sirito$^{2,‡}$, Alla Amcheslavky$^{4,‡}$, Tomek Czernuszewicz$^2$, Jordi Colonques-Bellmunt$^5$, Irma García-Alcover$^5$, Marzena Wojciechowska$^2$, Clare Bolduc$^1$, Zhihong Chen$^1$, Arturo López Castel$^5$, Ralf Krahe$^{2,3,6,§}$ and Andreas Bergmann$^{1,3,4,§}$

ABSTRACT

The myotonic dystrophies are prototypic toxic RNA gain-of-function diseases. Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are caused by different unstable, noncoding microsatellite repeat expansions – (CTG)$_{n}$ in DMPK and (CCTG)$_{n}$ in CNBP. Although transcription of mutant repeats into (CUG)$_{n}$DM1 or (CCUG)$_{n}$DM2 appears to be necessary and sufficient to cause disease, their pathomechanisms remain incompletely understood. To study the mechanisms of (CCUG)$_{n}$DM2 toxicity and develop a convenient model for drug screening, we generated a transgenic DM2 model in the fruit fly Drosophila melanogaster with (CCUG)$_{n}$ repeats of variable length (n=16 and 106). Expression of noncoding (CCUG)$_{106}$, but not (CCUG)$_{16}$, in muscle and retinal cells led to the formation of ribonuclear foci and mis-splicing of genes implicated in DM pathology. Mis-splicing could be rescued by co-expression of human MBNL1, but not by CUGBP1 (CELF1) complementation. Flies with (CCUG)$_{106}$ displayed strong disruption of external eye morphology and of the underlying retina. Furthermore, expression of (CCUG)$_{106}$ in developing retinae caused a strong apoptotic response. Inhibition of apoptosis rescued the retinal disruption in (CCUG)$_{106}$ flies. Finally, we tested two chemical compounds that have shown therapeutic potential in DM1 models. Whereas treatment of (CCUG)$_{106}$ flies with pentamidine had no effect, treatment with a PKR inhibitor blocked both the formation of RNA foci and apoptosis in retinae of (CCUG)$_{106}$ flies. Our data indicate that expression of expanded (CCUG)$_{n}$DM2 repeats is toxic, causing inappropriate cell death in affected fly eyes. Our Drosophila DM2 model might provide a convenient tool for in vivo drug screening.

KEY WORDS: Myotonic dystrophy, DM2, RNA toxicity, Drosophila, Muscleblind, Apoptosis

INTRODUCTION

Myotonic dystrophy (DM) is the most common adult-onset neuromuscular disorder (Harper, 2001). DM is characterized by myotonia, muscle weakness and wasting, as well as multi-systemic manifestations, including insulin resistance, gonadal atrophy, cataracts and neuropsychiatric symptoms (La Spada and Taylor, 2010; Udd and Krahe, 2012; Thornton, 2014). There are two genetically distinct types, DM1 and DM2, which are caused by similar noncoding repeat expansions in different genes: a (CTG)$_n$ expansion in the 3’ UTR of the DM1 protein kinase (DMPK) gene in DM1; and a (CCTG)$_n$ expansion in the first intron of the CCHC-type zinc finger nucleic acid binding protein (CNBP) gene [also known as zinc finger protein 9 (ZNF9)] in DM2 (La Spada and Taylor, 2010; Udd and Krahe, 2012; Timchenko, 2013; Thornton, 2014). Whereas expansion size generally correlates with disease severity in DM1 and is the basis for the observed pronounced anticipation, there does not appear to be a genotype/phenoype correlation in DM2 (Udd and Krahe, 2012). DM2 expansions up to 44 kb (11,000 CCTG) have been reported (Liquori et al., 2001; Day et al., 2003; Sallinen et al., 2004); the smallest expansions associated with clinically detectable manifestations are between 55 and 100 CCTG repeats (Liquori et al., 2001; Lucchiarì et al., 2008; Bachinski et al., 2009).

The prevailing paradigm is that both DM1 and DM2 are toxic RNA-mediated spliceopathies, mediated by the mutant expansions of normally polymorphic (CTG)$_n$ or (CCTG)$_n$ repeats: transcription into (CUG)$_{n}$DM1 or (CCUG)$_{n}$DM2 RNA is necessary and sufficient to cause disease (Osborne and Thornton, 2006; Klein et al., 2011; Sicot and Gomes-Pereira, 2013). Mutant RNAs accumulate in ribonuclear foci and interfere with RNA splicing, transcription and/or translation of downstream effector genes, resulting in the characteristic pleiotropic phenotype (Schosser and Timchenko, 2010; Jones et al., 2011; Sicot et al., 2011; Udd and Krahe, 2012; Timchenko, 2013).

Mechanistically, (CUG)$_{n}$DM1 or (CCUG)$_{n}$DM2 RNA foci sequester Muscleblind-like (MBNL) proteins, which are zinc-finger RNA-binding proteins involved in alternative RNA splicing (Miller et al., 2000; Mankodi et al., 2001, 2003; Kanadia et al., 2003; Pascual et al., 2006; Lee and Cooper, 2009; Schosser and Timchenko, 2010; Jones et al., 2011; Meola et al., 2013). MBNL proteins are highly conserved from flies to humans. The fruit fly Drosophila melanogaster has a single MBNL gene, muscleblind (mbl), which is involved in muscle development and photoreceptor neuron differentiation in the eye (Begemann et al., 1997; Artero et al., 1998; Pascual et al., 2006). Loss of mbl causes muscle defects and blindness, hence the name of the gene (Begemann et al., 1997; Artero et al., 1998). Similarly, in DM1 and DM2 patients [humans have three MBNL homologous genes: MBNL1-3 (Fardaei et al., 2002)], the sequestration of MBNL proteins in RNA foci reduces the amount of functional MBNL proteins available for proper splicing, resulting in a shift from the normal adult splice pattern to...
an inappropriate embryonic/fetal pattern of target transcripts (Miller et al., 2000; Mankodi et al., 2001; Jiang et al., 2004; Kanadia et al., 2006; Holt et al., 2009).

More than 20 transcripts have been shown to be mis-spliced in DM (Jiang et al., 2004; Gatchel and Zoghbi, 2005; Botta et al., 2007; Du et al., 2010). For example, aberrant splicing of the muscle-specific chloride channel CLCN1 and the insulin receptor (INSR) accounts for myotonia in DM (Savkur et al., 2001, 2004; Mankodi et al., 2002; Wheeler et al., 2007; Tonevitsky and Trushkin, 2009; Tang et al., 2012; Santoro et al., 2013). Other mis-spliced genes in DM include the muscle contractile proteins cardiac troponin (TNNT2) and skeletal muscle troponin (TNNT3) (Philips et al., 1998; Yuan et al., 2007; Vihola et al., 2010).

In addition to the MBNL family of proteins, at least two other RNA-binding proteins have been implicated in DM1. Expanded CUG repeats increase the activities of CUG-binding protein (CUGBP1; also known as CELF1) and dsRNA-dependent protein kinase (PKR; also known as EIF2AK2) (Tian et al., 2000; Timchenko et al., 2001a,b; Mankodi et al., 2003; Ward et al., 2010; Jones et al., 2011). Whether these factors are involved in DM2 is unclear.

There is currently no cure for DM. Most efforts to identify therapeutic modes of intervention are focused on the reversal of RNA toxicity. To develop a convenient model for drug screening, we generated a DM2 model in the fruit fly Drosophila melanogaster. We obtained transgenes that express noncoding transcripts of variable size, with the largest at 106 CCUG repeats (DM2-106). Transgenic DM2-106 flies recapitulate many features observed in the human disease condition. They form RNA foci in muscles and retinal cells and affect RNA splicing of splicing reporter genes. Although we did not observe muscle atrophy in DM2-106 flies, they displayed strong disruption in the external morphology of the eye and underlying retina. Expression of MBNL1, but not CUGBP1, was able to rescue the eye phenotype of DM2-106 flies. Furthermore, DM2-106 flies exhibited a strong apoptotic response in developing retinae, and inhibition of apoptosis rescued the retinal disruption. Finally, we tested two chemical compounds with therapeutic potential in DM1. Whereas treatment of DM2-106 flies with pentamidine had no effect, treatment with a PKR inhibitor blocked both the formation of RNA foci and apoptosis in retinae of DM2-106 flies. These data suggest that the Drosophila DM2 model described here may provide a suitable tool for drug screening.

**RESULTS**

Transcripts with expanded (CCUG)n repeats form RNA foci

The smallest reported DM2 expansions associated with clinically detectable manifestations are between 55 and 100 CCUG repeats (Liquori et al., 2001; Lucchiani et al., 2008; Bachinski et al., 2009). To generate a DM2 model in Drosophila, we prepared two transgenes: a control transgene expressing a noncoding transcript with 16 CCUG repeats (DM2-106) (Fig. 1A). Because the (CCTG)DM2 expansion is part of a complex polymorphic motif (Bachinski et al., 2003, 2009) of the form (TG)h(TCTG)k(CCTG)N-16 and the (TG)h(TCTG)k polymorphic repeats have been shown to affect DNA structure (Edwards et al., 2009), we included a (TG)h(TCTG)k tract in our CCTGDM2 constructs. Both control and DM2 transgenes contained the polymorphic (TG)h(TCTG)k repeats upstream of the (CCTG)h tract: the N-16 allele had a (TG)22(TCTG)2(CCTG)106 motif, while the DM2-106 allele had a (TG)22(TCTG)2(CCTG)106 motif (Fig. 1A). These transgenes are under the control of a UAS promoter (Brand and Perrimon, 1993) and expression can be induced using convenient Gal4 drivers, such as muscle-specific Mhc-Gal4 and eye-specific GMR-Gal4.

Because myotonia and muscle wasting are associated with human DM2, we first expressed the control and disease transgenes using Mhc-Gal4 and analyzed the morphology of the indirect flight muscle (IFM). As nuclear retention of RNA-protein aggregates (foci) is a hallmark of DM2 (Mankodi et al., 2003; Jones et al., 2011; Udd and Krahe, 2012; Meola et al., 2013), we first determined that DM2-106 flies mirror this disease-linked trait and performed FISH analysis to detect foci in the nucleus of IFM cells of DM2-106 flies. No foci were

![Fig. 1. A Drosophila DM2 model forms nuclear CCUG foci.](image-url)

(A) Schematic (not to scale) of the noncoding CCTG repeat constructs used in this study. The control contains (CCTG)16 repeats (N-16), which is non-toxic in humans. The mutant construct contains (CCTG)106 repeats (DM2-106). Both constructs are preceded by polymorphic (TG)h(TCTG)k repeats, as indicated, that are also part of the complex human repeat motif. These constructs are under control of the UAS promoter. (B) In situ hybridization using a locked nucleic acid (LNA) probe was performed on 15 μm cryosections of thoracic muscles of flies expressing DM2-106 and control repeats using the myosin Mhc-Gal4 driver. DM2-106 expression is associated with the presence of ribonuclear foci (red) in DAPI-stained nuclei (blue), whereas no foci are detected in controls using the same Gal4 driver. Two representative foci are indicated (arrows). (C) Quantification of nuclei with ribonuclear foci in control and DM2-106 muscle cells using Mhc-Gal4. Error bars indicate s.d.
detected in control IFM, whereas more than 50% of the cells analyzed had nuclear foci in DM2-106 flies (Fig. 1B, C), demonstrating that 106 CCUG repeats are sufficient to cause biochemical changes. The average fraction of nuclei with ribonuclear foci in DM2-106 muscle cells is similar to that observed in a DM1 fly model expressing 480 CTG repeats (Garcia-Alcover et al., 2014).

**Expression of DM2-106 in Drosophila muscles causes mis-splicing**

In order to evaluate DM2-106 flies as a suitable DM2 model, we examined mis-splicing events in transgenic flies expressing the 106 CCUG repeats in IFM. We studied alternative splicing of the endogenous Fhos gene (Fig. 2A), which showed aberrant splicing regulation in DM1 flies expressing a (CTG)480 tract (Garcia-Lopez et al., 2008) (see also Fig. 2B). For this analysis, we used two different transgenes for control and DM2-106 constructs, located on chromosomes 2 and 3. Expression of both DM2-106 transgenes increased the frequency at which exon 24 was aberrantly included (Fig. 2B); quantification revealed an increase from ~30% in N-16 control flies to >70% in DM2-106 flies (Fig. 2C), similar to DM1. The MBNL proteins are sequestered in (CCUG)DM2 foci and have been implicated as important mediators of DM2-associated

---

**Fig. 2. DM2-106 expression in muscle causes mis-splicing of MBNL1-dependent transcripts.** (A) Outline of the intron/exon structure of Fhos (CG42610) showing the exons implicated in the splicing event studied. Wild-type flies mainly skipped exon 24 (solid line), whereas DM2-106 expression in IFM led to aberrant inclusion of exon 24 (dotted lines). Arrows indicate primers used for semi-quantitative PCR analysis. (B) Agarose gel and quantification of Fhos RT-PCR products from IFM expressing control (N-16) and DM2-106 transgenes located on chromosomes 2 and 3. These transgenes were driven by Mhc-Gal4. Flies that only contain the Mhc-Gal4 driver without a UAS transgene show an average frequency of exon 24 inclusion of ~30%. Compared with this control, expression of normal repeat length (CCUG)16 does not significantly alter Fhos splicing, whereas in the (CCUG)106 repeat-expressing cells exon 24 is retained at ~70%, levels similar to those of DM1 flies expressing an interrupted 480 CUG repeat sequence (iCUG)480. (D,E) Agarose gel and quantification of Fhos RT-PCR products from flies expressing the indicated transgenes with the Mhc-Gal4 driver. Simultaneous expression of human MBNL1 and DM2-106 induces exon 24 exclusion, restoring wild-type levels (Mhc-Gal4 only). Error bars represent s.d. and each experiment was repeated at least twice in adults of 0-5 days of age. (F-H) Luminescence levels of Mhc-Gal4>UAS-INSR,DM2-106 normalized to the levels of Mhc-Gal4>UAS-minigene,UAS-GFP. Relative luminescence decreased from 100% in control flies to 78% for the human INSR reporter minigene (F), 38% for TNNT2 (cTNT) (G) and 68% for mouse Tnnt3 (H). RLU, relative light units. **P<0.005, ***P<0.001 (Student’s t-test). (F’) RT-PCR analysis of the INSR splicesensor in N-16 and DM2-106 background. The percentage is the average of two experiments.
spliceopathy. To validate an involvement of MBNL factors in DM2 flies, we co-expressed the human MBNL1 gene and DM2-106 in Drosophila IFM. As shown in Fig. 2D, MBNL1 expression rescued exon 24 inclusion levels in IFM in the presence of (CCUG)\textsubscript{106}, unlike GFP protein, which was used as a negative control in this co-expression experiment. The frequency of disease-linked exon 24 inclusion was reduced from 73\% (DM2-106+GFP) to 48\% (DM2-106+MBNL1), close to control levels in the non-disease situation (38\%) (Fig. 2E).

The suitability of our Drosophila DM2 system as a disease model was further demonstrated by the observation that different spliceosensor luciferase reporters, which express specific mammalian reporter mini-genes for identified mis-splicing events in DM1 and DM2 (human INSR exon 11 and mouse Tnnt3 fetal exon) (Savkur et al., 2004; Vihola et al., 2010; Garcia-Alcover et al., 2014), were also responsive to the presence of expanded CCUG repeats (Fig. 2F-H). In addition, we tested a Tnnt2 exon 5 spliceosensor reporter that shows mis-splicing in DM1 (Philips et al., 1998). All three spliceosensor reporters revealed alternative splicing aberrations, resulting in reduced luciferase luminescence, when (CCUG)\textsubscript{106} repeats were expressed in the IFM (Fig. 2F-H). To verify that the significant changes in luciferase luminescence were due to mis-splicing, we examined the splicing pattern of the INSR spliceosensor reporter directly by RT-PCR in our DM2 fly model. In the Drosophila DM1 model, two splice isoforms of the INSR spliceosensor were detectable due to the inclusion (isoform B) or exclusion (isoform A) of an alternative exon between exons 11 and 12 (Garcia-Alcover et al., 2014). Isoform A is preferentially observed in the disease state (Garcia-Alcover et al., 2014). In the N-16 controls expressing (CCUG)\textsubscript{16}, isoform A was present at 42.5\% (Fig. 2F’), consistent with the previous report by Garcia-Alcover et al. (2014). By contrast, in the presence of expanded (CCUG)\textsubscript{106} repeats (DM2-106), the relative amount of isoform A increased to 65\% (Fig. 2F’), which correlated with the decreased luciferase luminescence observed in Fig. 2F. These results demonstrated that DM2-106 transgenic flies display a spliceopathy phenotype similar to that seen in human DM2 patients and thus validate it as a suitable DM2 model.

**Expression of (CCUG)\textsubscript{106} in Drosophila IFM does not cause muscle atrophy**

To study the extent of (CCUG)\textsubscript{106} toxicity in our DM2 model, we analyzed IFM samples expressing control or expanded (CCUG)\textsubscript{106} (N-16 or DM2-106) for morphological defects similar to those described in patients (Vihola et al., 2003; Bassez et al., 2008). However, in contrast to the phenotypic alterations of the IFM in DM1 models (Fig. 3C), no significant differences were observed between the IFMs of control and expanded (CCUG)\textsubscript{106}-expressing flies (Fig. 3A,B, quantified in Fig. 3D). DM2-106 flies appeared to be able to fly normally and even aged flies (40 days) did not display any obvious flight defects. These results demonstrated that although (CCUG)\textsubscript{106} repeats are sufficient to cause biochemical abnormalities, they are not sufficient to cause morphological and behavioral phenotypes in the IFM.

**Expanded (CCUG)\textsubscript{106} repeats cause severe disorganization of eye morphology, which is modified by loss or gain of MBNL proteins**

Because (CCUG)\textsubscript{106}-expressing flies did not show significant phenotypic alterations in the IFM, we turned our focus to a different phenotype commonly observed in DM2 pathogenesis, namely ocular manifestations. For that purpose, we expressed control (N-16) and DM2-106 transgenes using GMR-Gal4 in the posterior half of developing eye imaginal discs, which form the retina during late larval and pupal stages. Adult flies expressing the (CCUG)\textsubscript{106} transgenes developed eyes of severely disorganized morphology (Fig. 4C). By contrast, control GMR-Gal4>N-16 flies displayed only mildly rough eyes, as compared with GMR-Gal4-only eyes (Fig. 4A,B). Both transgenes are expressed at similar levels (Fig. 4H). Thus, in contrast to the IFM, expression of expanded (CCUG)\textsubscript{106} repeats caused severe phenotypic abnormalities in the fly eye. A similar observation has recently been reported for a different DM2 fly model (Yu et al., 2015).

As described above, MBNL proteins are thought to be involved in DM2 pathogenesis. To confirm this in our DM2 fly model, we examined whether alterations to the gene dose of Drosophila mbl would modify the DM2-106 phenotype. In a heterozygous mbl\textsuperscript{+/–} background, the eye phenotype of adult DM2-106 flies is severely enhanced (Fig. 4E). The eyes are rougher and more disorganized, and often also reduced in size. Phenotypic rescue is observed when the human MBNL1 protein is overexpressed in DM2-106 flies, which suppressed the DM2-106 eye phenotype (Fig. 4F). The eyes appear almost normal and ommatidial integrity is visible.

Expression of a control UAS transgene, UAS-GFP, does not
affect the DM2-106 eye phenotype (Fig. 4D), suggesting that the rescue by MBNL1 expression is not due to the additional UAS transgene. Immunolocalization reveals that MBNL1 protein is localized in CCUG foci (Fig. 4I–I″, arrows), but we also observe aggregates of MBNL1 protein outside of CCUG foci (Fig. 4I, I″, arrowheads).

Another protein implicated in the pathology of DM1 is CUGBP1 (Timchenko et al., 2001a,b; de Haro et al., 2006; Jones et al., 2011; Timchenko, 2013). However, in contrast to MBNL1, expression of human CUGBP1 has little or no effect on the morphology of DM2-106 eyes (compare Fig. 4G with 4C).

DM2-106 causes severe disruption of retinal organization

To further characterize the eye phenotype of GMR>DM2-106 flies, we examined the underlying retinal morphology. The developing retina is fully differentiated at 42 h after puparium formation (APF). In wild-type retinae at that stage, photoreceptor neurons, cone cells and pigment cells are highly organized in a stereotypical pattern to form the individual ommatidia. Each ommatidium contains four concentrically aligned cone cells surrounded by pigment cells (Fig. 5A″). In GMR-Gal4>N-16 control flies, this pattern is not significantly disturbed (Fig. 5A′-A″). By contrast, in GMR>DM2-106 retinae the precise cellular arrangement is severely disrupted, with photoreceptor neurons, cone cells and pigment cells irregularly positioned and numbered (Fig. 5B-B″). Ommatidia were fused and ommatidial identity was not observed.

Apoptosis induced by DM2-106 causes retinal disruption and disorganization

Recently, apoptosis has been implicated in muscle degeneration in a Drosophila DM1 model (Bargiela et al., 2015). Therefore, we examined whether apoptosis contributes to the retinal phenotype in GMR>DM2-106 transgenic flies. In GMR-Gal4>N-16 control flies, no or very little apoptosis occurs in eye imaginal discs (Fig. 6A). However, in GMR>DM2-106 eye imaginal discs, apoptosis is strongly induced in the GMR domain in the posterior half of the larval disc (Fig. 6B, arrow), suggesting that (CCUG)106 RNA triggers apoptosis. P35 is a potent inhibitor of apoptosis, and specifically inhibits effector caspases in flies (Hay et al., 1994; Hawkins et al., 2000; Meier et al., 2000). Co-expression of p35 together with DM2-106 under GMR-Gal4 control suppressed the apoptotic phenotype in larval eye imaginal discs (Fig. 6C). Because P35 potently suppressed apoptosis in DM2-106 flies, we were able to dissect the relative contribution of apoptosis to...
Feasibility of the DM2-106 model for chemical screening

The data presented here suggest that expression of DM2-106 in the Drosophila retina mimics pathological manifestations seen in the human condition, including the formation of toxic CCUG foci, as well as retinal disorganization and degeneration. Therefore, DM2-106 might provide a suitable and convenient model for drug screening and identification of lead compounds (Garcia-Alcover et al., 2013). To assess the feasibility of our DM2-106 model for drug screening, we tested two compounds that have previously been shown to have therapeutic potential in DM1 models. Pentamidine is a dsRNA-intercalating drug that was found to disrupt the MBNL1-CUG repeat complex in DM1 (Warf et al., 2009). It was recently reported that pentamidine treatment can also rescue cardiac dysfunction in a Drosophila DM1 model (Chakraborty et al., 2015). The second drug, the oxindole/imidazole derivative C16, is an inhibitor of the dsRNA-dependent protein kinase PKR (PKR-I), which is activated by expanded CUG repeats in DM1 (Tian et al., 2000, 2005; Huichalaf et al., 2010; Wojciechowska et al., 2014). As an assay for drug treatment, we examined the ability of the selected inhibitors to block the formation of toxic CCUG foci in the DM2-106-expressing retina (Fig. 7B). Interestingly, these foci were not only nuclear, but could also be observed in the cytoplasm (Fig. 7B, arrows). Pentamidine treatment up to 350 μM, a concentration that has been shown to be effective in DM1 (Warf et al., 2009), has no visible effect on RNA foci formation in the DM2-106 model (Fig. 7C-E). By contrast, treatment with PKR-I showed a pronounced decrease in the abundance of CCUG RNA foci in a concentration-dependent manner: 4 μM PKR-I caused a significant reduction of RNA foci, and 7 μM completely disrupted foci formation (Fig. 7F-H), resembling wild-type retinae (Fig. 7A). Consistently, loss of CCUG foci by PKR-I treatment correlated with reduction and loss of apoptosis (Fig. 7I-L). These examples illustrate that the DM2-106 retina might provide a convenient model for drug screening in flies.

The suppression of foci formation and apoptosis by PKR-I suggests that PKR activity is increased in the retinae of DM2-106 expressing pathogenic CCUG repeats. Activation of PKR by expanded CUG repeats in DM1 has been reported (Tian et al., 2000;
untreated concentration-dependent manner. (I-L) Eye imaginal discs from control (I), (oxindole/imidazole derivative C16, PKR-I) suppressed foci formation in a retinae from control (A), untreated foci formation up to a concentration of 350 μM PKR-I (Fig. 8D). These data suggest that PKR activity is strongly induced in the presence of 106 CCUG repeats in the retina.

**DISCUSSION**

The goal of this work was to develop a fly model that can be used for drug screening to identify therapeutic compounds for potential treatment of DM2 patients. The rationale was that many cell biological processes, including apoptosis, alternative RNA splicing and the genes/proteins involved, are highly conserved between flies and humans. Furthermore, the genetic tools available in *Drosophila* allow for rapid characterization of the underlying phenotypes. Finally, experimentation with flies is relatively inexpensive and the short generation time enables rapid genetic and chemical screening.

Here, we describe a DM2 fly model that expresses 106 CCUG repeats in a non-coding transcript (DM2-106). Several features of DM2-106 flies indicate that expression of expanded (CCUG)106 RNA elicits molecular and cellular phenotypes similar to those associated with DM2 pathology in human patients. DM2-106 transcripts aggregate in RNA foci that are predominantly nuclear, but can also be observed in the cytoplasm, at least in retinal cells. Cytoplasmic (CCUG)DM2 foci have also recently been described in human HeLa cells (Jones et al., 2015). These RNA foci sequester MBNL proteins, which causes mis-splicing in muscles similar to that seen in human DM2 patients. Although we did not observe muscle atrophy in DM2-106 flies, the retinae and eyes of these flies were severely disrupted. Functional complementation by overexpression of human MBNL1 protein in GMR-DM2-106 rescued the retinal degeneration. Furthermore, inhibition of apoptosis restored the retinal pattern and eye morphology, suggesting that expression of (CCUG)106 in DM2-106 flies induced apoptosis as the underlying cause of the retinal degeneration. The involvement of apoptosis in retinal degeneration is consistent with the recent finding that apoptosis also contributes to muscle degeneration in a *Drosophila* DM1 model (Bargiela et al., 2015). In a pilot drug screening experiment in DM2-106 eyes, we found that an inhibitor of PKR activity efficiently blocked formation of RNA foci and apoptosis, whereas pentamidine failed to inhibit foci formation. Finally, we show that pathogenic (CCUG)n DM2 repeat expansions activate the dsRNA-dependent protein kinase PKR, similar to previous reports in DM1 (Tian et al., 2000; Huichalaf et al., 2010; Wojciechowska et al., 2014). Taken together, these data suggest that our DM2-106 fly model provides a convenient tool for drug screening.

While this work was under way, another group published a different DM2 model in *Drosophila* (Yu et al., 2015). These authors were able to express more than 700 CCUG repeats in flies. Consistent with our observations, expression of (CCUG)700 repeats caused retinal and eye disruption. Interestingly, muscle atrophy was also not reported (Yu et al., 2015), suggesting that in *Drosophila* the eye is perhaps more sensitive to RNA perturbations than skeletal muscle. In this context, it is worth noting that muscle weakness and atrophy are generally weaker in DM2 patients than in DM1 (Udd and Krahe, 2012). Alternatively, it is possible that there is an expansion threshold that underlies tissue-specific manifestations of the overall DM2 phenotype and that the expression of (CCUG)106 repeats is insufficient in itself to induce muscle phenotypes due to mis-splicing, but could involve the recently identified RAN (repeat-associated non-ATG) translation as another pathomechanism (Zu et al., 2011).

Despite the fact that DM1 and DM2 share many pathological manifestations, they are not identical diseases (Udd and Krahe, 2012). Additionally, while this work was under way, another group published a different DM2 model in *Drosophila* (Yu et al., 2015). These authors were able to express more than 700 CCUG repeats in flies. Consistent with our observations, expression of (CCUG)700 repeats caused retinal and eye disruption. Interestingly, muscle atrophy was also not reported (Yu et al., 2015), suggesting that in *Drosophila* the eye is perhaps more sensitive to RNA perturbations than skeletal muscle. In this context, it is worth noting that muscle weakness and atrophy are generally weaker in DM2 patients than in DM1 (Udd and Krahe, 2012). Alternatively, it is possible that there is an expansion threshold that underlies tissue-specific manifestations of the overall DM2 phenotype and that the expression of (CCUG)106 repeats is insufficient in itself to induce muscle phenotypes due to mis-splicing, but could involve the recently identified RAN (repeat-associated non-ATG) translation as another pathomechanism (Zu et al., 2011).
2012). For example, they affect different types of muscle and the neurological symptoms in DM2 are generally less severe (Thornton, 2014; Ulane et al., 2014). We also observed differences between the DM1 and DM2 models in Drosophila. Whereas expression of CUGBP1 enhanced the DM1 phenotype (de Haro et al., 2006), it had no obvious effect on the eye phenotype of GMR-DM2-106 flies. Furthermore, pentamidine treatment, which was shown to be effective in DM1 (Chakraborty et al., 2015), had no effect on foci formation in DM2-106. Therefore, comparative analysis of DM1 and DM2 fly models might reveal additional differences that underlie the two diseases and thereby provide important insights into the etiology of the human phenotypes.

Our pilot drug screen revealed that the DM2-106 Drosophila model is well suited for drug screening. Treatment of DM2-106 flies with increasing concentrations of a PKR inhibitor disrupted CCUG RNA foci formation and apoptosis in eye imaginal discs, the larval precursor tissue of adult retinae and eyes. PKR encodes a dsRNA-dependent protein kinase, which was found to be activated in DM1. Our data suggest that PKR activity is also induced by expanded (CCUG), DM2 repeats. Unfortunately, although PKR-I feeding of larvae disrupted CCUG foci formation in GMR-DM2-106 eye imaginal discs, the resulting eye phenotype of adult flies was not rescued (Fig. S1). A possible explanation for this observation is that flies stop feeding after the larval stage, so that during pupal stages the eye phenotype can still develop. Nevertheless, we are confident that modeling of DM2 in Drosophila will further contribute to our understanding of the pathology of DM2 and provide an excellent platform for genetic and chemical (drug) screening.

**MATERIALS AND METHODS**

**Generation of control and expanded (CCUG), repeat expression clones**

The (CCTG)DM2 expansion is part of a complex polymorphic motif (Bachiński et al., 2009) of the form (TG), (TCTG), (CCTG), (G/TCTG), (CCTG),. DM2 expansions can be as large as 40 kb with the CCTG motif uninterrupted (Liquori et al., 2001; Bachinski et al., 2003; Sallinen et al., 2004). Reported normal alleles have repeat tract lengths of up to 26 CCTG motifs with one or more interruptions (Bachiński et al., 2009). The smallest reported DM2 expansions associated with clinically detectable manifestations are between 55 and 100 CCTG repeats (Liquori et al., 2001; Lucchiarì et al., 2008; Bachinski et al., 2009). Because this complex polymorphic repeat motif has been shown to have an effect on DNA structure (Edwards et al., 2009), we included the (TG), (TCTG), (CCTG), repeats with 16 to 189 pure (CCTG), motifs. Cloned repeats were verified by sequencing to ensure purity of the expanded (CCTG), repeat tract. In order to express the (CCTG), repeats in Drosophila, mutant fragments containing 106 repeats with the upstream region were recovered from the TOPO vector and cloned into pUAST (Brand and Perrimon, 1993). The same cloning procedure was used with genomic DNA from a normal individual to generate the control vector containing a normal (CCTG), allele. The presence and the length of the (CCTG), repeats in the pUAST vector were confirmed by sequencing in both directions: DM2-106, (TG), (TCTG), (CCTG),; and N-16, (TG), (TCTG), (CCTG),.

**Generation of the MBNL1 expression clone**

The human MBNL1 clone was obtained from OriGene (TrueClone accession number NM_006560.2). This variant is the predominant transcript and encodes isoform 1. To generate the expression clone, we used the same procedure as for the MBNL1 expression clone, except for the SpeI digestion, since insert and vector were readily distinguishable by size in gel electrophoresis.

**Fly husbandry**

Flies were raised on normal corn agar and crosses were incubated at 25°C. The following mutants and transgenic stocks were used: UAS-[CCTG]16 (control); UAS-[CCTG]106 (DM2-106); UAS-MBNL1; UAS-CUGBP1; UAS-p35; Mhc-Gal4; GMR-Gal4; mhcRGS85. Generation and management of DM1 spliceosensor flies was as described (Garcia-Alcover et al., 2014). To simplify crosses, DM2-106 transgenics on chromosome 2 or 3 were recombined with GMR-Gal4 on the same chromosome to yield GMR-DM2-106 on chromosome 2 or 3. Fly eyes were photographed using a Zeiss Axio Imager Z1 compound microscope.

**Drug treatment**

Fly food was supplemented with drugs at the final concentrations indicated in Figs 7, 8 and Fig. S1. Pentamidine was obtained from Sigma-Aldrich (439843) and PKR-I from Calbiochem (527451). Because PKR-I needs to be dissolved in 100% DMSO, a DMSO-only control was also performed. The same volume of DMSO-containing solutions was mixed into the food.

**Reverse transcription PCR (RT-PCR) analysis**

For Phos and INSR splicing assays, total RNA was extracted from ~50 adult flies with Tri Reagent (Sigma) following the manufacturer’s instructions. Contaminating DNA was degraded by RNase-free Dnase I (Thermo Scientific). Reverse transcription was performed with SuperScript II reverse transcriptase (Invitrogen) following the manufacturer’s guidelines. GoTaq polymerase (Promega) was used for PCR amplification with primers (5’-3’) for Fos-F (GTCATGGAGTCGAGCAGTGA) and Fos-R (TGTGATGCG- AGATCAGTGAGATAG). For quantification of Phos and INSR transcript levels (Fig. 4H), total RNA was extracted from Drosophila eye imaginal discs using TRIzol reagent (Invitrogen). cDNA conversion was performed using the SuperScript II RNase H-Reverse Transcriptase Kit (Invitrogen). Quantitative PCR (qPCR) was performed using cDNA template and SYBR Green Power Mix (Applied
 Biosystems). Three sets of primers flanking the CCUG repeats were designed in the pUAST vector used to clone the transgenes: primer set #1, Fwd GTGTTGGAATGCTTTAAT and Rev GAGGAGTAGAATGTTGAGA; primer set #2, Fwd AAGAGAAGAAATTAGAAAG and Rev AGAAAAAGCAAGAAGAG; primer set #3, Fwd CATGGTAGATGAGTAGGCTACT and Rev TACCAATCTGAAGAGATGC. Transcript levels of Riboosomal protein 49 (Rpl49; also known as Rpl32) were used for normalization across samples, using primers Fwd ACCAGCTCAAGATGACCATCC and Rev CTGTGCATCGTCGAACCGAT.

**Fluorescence in situ hybridization (FISH)**

FISH analysis was performed as described (Salisbury et al., 2009), except that *Drosophila* tissue was used. Imaginal discs were imaged by confocal microscopy. RNA-FISH analysis of drug-treated retinae was performed with a (CUGG)10 probe.

For muscle preparation, thoraces of 0- to 5-day-old *MHC-Gal4-UAS-(CCTG)106* or *MHC-Gal4-UAS-(CCTG)16* females were dissected, embedded in OCT (Fisher HealthCare), frozen in liquid nitrogen and stored at −80°C until processed. At least five 40× magnification images of different focal planes along the z-axis were taken using a Leica DM2500 microscope for DAPI (UV channel) and Cy3 (green channel). The percentage of cells with foci was compared between counted and at least three individuals were analyzed for each compound.

**Luciferase readout**

Three 0- to 5-day-old adult flies were placed in each well of a flat-bottom 96-well plate (Daslab, Barcelona, Spain) and homogenized in 150 μl 1× reporter lysis buffer (Promega). Then, 50 μl of the homogenate was transferred to a new white 96-well plate (Sterilin). Lysate luminescence was measured with an Envision plate reader (PerkinElmer) after dispensing 15 μl Luciferase Assay Reagent (Promega) with the Envision injector. At least 60 wells were analyzed for each genotype studied.

**Muscle histology**

*Drosophila* thoraces (7-12 days old) were embedded in Epon for semi-thin transverse sectioning as previously described (Tomlinson and Ready, 1987). Relative muscle areas of at least six different thoraces were calculated as described (Garcia-Lopez et al., 2011).

**Immunohistochemistry**

At least 20 imaginal discs per experiment were dissected from late third instar larval and pupal retinae from 42-h-old pupae. They were fixed and stained using standard protocols (Fogarty and Bergmann, 2014). TUNEL was performed using a TUNEL assay kit (Roche Life Sciences) according to the manufacturer’s instructions. Antibodies to the following primary antigens were used: ELAV [rat; 1:50; Developmental Studies Hybridoma Bank (DSHB)]; Cut (mouse; 1:50; DSHB); Dlg (rabbit; 1:100; from Kwang-Wook Choi, Korea Advanced Institute of Science and Technology, Daejeon, South Korea); MBNL1 (rabbit; 1:2000; from Charles Thornton, University of Rochester Medical Center, Rochester, NY, USA); cleaved Caspase 3 (rabbit; 1:200; Cell Signaling Technology, 9661); and elf2α (rabbit; 1:100; Cell Signaling Technology, 3957). Secondary antibodies were donkey Fab fragments from Jackson ImmunoResearch (715-166-151, 711-096-152, 712-606-153, 711-166-152; all at 1:600). Nuclei were visualized by Hoechst and DAPI staining. Fluorescent images were taken with an Olympus Optical FV500 confocal microscope.

**Acknowledgements**

We thank Linda Bachinski, Juan Botas, Kwang-Wook Choi, Marek Mlodzik, Bruce Hay, Thomas Cooper, Maurice Swanson, Nicholas Webster, Eric Olson, Charles Thornton, Jillian Lindblad, the Bloomington Drosophila Stock Center and the Developmental Studies Hybridoma Bank, Iowa City, IA, USA, for providing plasmids, fly stocks, antibodies and other reagents. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Competing interests**

The authors declare no competing or financial interests.

**Author contributions**

Conceptualization: R.K., A.B.; Methodology: M.S., T.C.; Formal analysis: V.B.Y., A.A., A.L.C., R.K., A.B.; Investigation: V.B.Y., M.S., A.A., J.C.-B., I.G.-A., M.W., C.B., Z.C.; Writing - original draft: A.B.; Writing - review & editing: A.L.C., R.K., A.B.; Supervision: A.L.C., R.K., A.B.; Funding acquisition: R.K., A.B.

**Funding**

This work was supported by the National Institute of General Medical Sciences (NIGMS) under award number R35 GM118330 to A.B., and by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under award number AR068491. The Muscular Dystrophy Association (RG 4321) and the Alice Kiberg Reynolds Foundation for Genetics to R.K. Supported in part by the National Institutes of Health/National Cancer Institute under award number P30 CA016672 and used for the Sequencing and Microarray Facility. Deposited in PMC for immediate release.

**Supplementary information**

Supplementary information available online at http://dmm.biologists.org/lookup/doi/10.1242/dmm.026179.supplemental

**References**

Artero, R., Prokop, A., Paricio, N., Begemann, G., Pueyo, I., Mlodzik, M., Perez-Alonso, M. and Bayliss, M. K. (1998). The muscle blind gene participates in the organization of Z-bands and epidermal attachments of Drosophila muscles and is regulated by Dmz1. Dev. Biol. 195, 131-143.

Bachinski, L. L., Udd, B., Meola, G., Sansone, V., Bassez, G., Eymard, B., Thornton, C. A., Mosley, R. T., Harper, P. S., Rogers, M. T. et al. (2003). Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am. J. Hum. Genet. 73, 835-848.

Bachinski, L. L., Czernuszewicz, T., Ramaghi, L. S., Suominen, T., Shriver, M. D., Udd, B., Siciliano, M. J. and Krahe, R. (2009). Premutation allele pool in myotonic dystrophy type 2. Neurology 72, 490-497.

Bargiela, A., Cerro-Herreros, E., Fernandez-Costa, J. M., Vilchez, J. J., Llumusi, B. and Artero, R. (2015). Increased autophagy and apoptosis contribute to muscle atrophy in a myotonic dystrophy type 1 Drosophila model. Dis. Model. Mech. 8, 679-690.

Bassez, G., Chapoy, E., Bastuj-Garin, S., Radvanyi-Hoffman, H., Authier, F.-J., Pellissier, J. F., Eymard, B. and Gherardi, R. K. (2008). Type 2 myotonic dystrophy can be predicted by the combination of type 2 muscle fiber central nucleation and scattered atrophy. J. Neuropathol. Exp. Neurol. 67, 319-325.

Begemann, G., Paricio, N., Artero, R., Kiss, I., Perez-Alonso, M. and Mlodzik, M. (1997). Muscleblind, a gene required for photoreceptor differentiation in Drosophila, encodes novel nuclear Cys3His-type zinc-finger-containing proteins. Development 124, 4321-4331.

Botta, A., Vallo, L., Rinaldi, F., Bonifazi, E., Amati, F., Biancolella, M., Gambardella, S., Mancinelli, E., Angelini, C., Meola, G. et al. (2007). Gene expression analysis in myotonic dystrophy: indications for a common molecular pathogenic pathway in DM1 and DM2. Gene Expr. 13, 339-351.

Brand, A. H. and Perrimon, N. (1993). Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118, 401-415.

Chakraborty, M., Selma-Soriano, E., Magny, E., Couso, J. P., Perez-Alonso, M., Charler-Berguerand, N., Artero, R. and Llumusi, B. (2015). Pentamidine rescues contractility and rhythmicity in a Drosophila model of myotonic dystrophy heart dysfunction. Dis. Model. Mech. 8, 1569-1578.

Day, J. W., Ricker, K., Jacobsen, J. F., Rasmussen, L. J., Dick, K. A., Kress, W., Schneider, C., Koch, M. C., Beilman, G. J., Harrison, A. R. et al. (2003). Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 60, 657-664.

de Haro, M., Al-Ramahi, I., De Gouyon, B., Ukanli, L., Rosa, A., Faustino, N. A., Ashizawa, T., Cooper, T. A. and Botas, J. (2006). MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1. Hum. Mol. Genet. 15, 2138-2145.

Du, H., Cline, M. S., Osborne, R. J., Tuttle, D. L., Clark, T. A., Donohue, J. P., Hall, P. M., Shiue, L., Swanson, M. S., Thornton, C. A. et al. (2010). Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat. Struct. Mol. Biol. 17, 187-193.

Edwards, S. F., Sirito, M., Krahe, R. and Sinden, R. R. (2009). A Z-DNA sequence reduces slipped-strand structure formation in the myotonic dystrophy type 2 (CCTG)n expansion model. Proc. Natl. Acad. Sci. USA 106, 3270-3275.

Fardaei, M., Rogers, M. T., Thorpe, H. M., Larkin, K., Hamshere, M. G., Harper, P. S. and Brook, J. D. (2002). Three proteins, MBNL, MBLL and MBXL, reduce slipped-strand structure formation in the myotonic dystrophy type 2 (CCTG)n expansion model. Proc. Natl. Acad. Sci. USA 99, 15817-15822.
(2010). Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2. *Acta Neuropathol.* **119**, 465-479.

Ward, A. J., Rimer, M., Killian, J. M., Dowling, J. J. and Cooper, T. A. (2010). CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. *Hum. Mol. Genet.* **19**, 3614-3622.

Warf, M. B., Nakamori, M., Matthys, C. M., Thornton, C. A. and Berglund, J. A. (2009). Pentamidine reverses the splicing defects associated with myotonic dystrophy. *Proc. Natl. Acad. Sci. USA* **106**, 18551-18556.

Wheeler, T. M., Lueck, J. D., Swanson, M. S., Dirksen, R. T. and Thornton, C. A. (2007). Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. *J. Clin. Invest.* **117**, 3952-3957.

Williams, D. D., Pavitt, G. D. and Proud, C. G. (2001). Characterization of the initiation factor eIF2B and its regulation in Drosophila melanogaster. *J. Biol. Chem.* **276**, 3733-3742.

Wojciechowska, M., Taylor, K., Sobczak, K., Napierala, M. and Krzyzosiak, W. J. (2014). Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1. *RNA Biol.* **11**, 742-754.

Yu, Z., Goodman, L. D., Shieh, S.-Y., Min, M., Teng, X., Zhu, Y. and Bonini, N. M. (2015). A fly model for the CUG-repeat expansion of myotonic dystrophy type 2 reveals a novel interaction with MBNL1. *Hum. Mol. Genet.* **24**, 954-962.

Yuan, Y., Compton, S. A., Sobczak, K., Stenberg, M. G., Thornton, C. A., Griffith, J. D. and Swanson, M. S. (2007). Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs. *Nucleic Acids Res.* **35**, 5474-5486.

Zu, T., Gibbens, B., Doty, N. S., Gomes-Pereira, M., Huguet, A., Stone, M. D., Margolis, J., Peterson, M., Markowski, T. W., Ingram, M. A. C. et al. (2011). Non-ATG-initiated translation directed by microsatellite expansions. *Proc. Natl. Acad. Sci. USA* **108**, 260-265.